Stroke · atherosclerotic cardiovascular disease
EDTA showed no clear difference in stroke compared with placebo (low certainty).
1 finding from 1 review
Ankle brachial index · atherosclerotic cardiovascular disease
1 finding from 1 review
Maximum walking distance · atherosclerotic cardiovascular disease
1 finding from 1 review
Cervical dystonia‐specific improvement · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.23 [1.05, 1.43]
Studies not reported
Moderate
Subjective participant assessment at 4 weeks; 755 participants(6 RCTs) · cervical dystonia
Botulinum toxin type A leads to higher subjective participant assessment at 4 weeks; 755 participants(6 RCTs) compared with placebo (high certainty).
1 finding from 1 review
RR 2.19 [1.78, 2.7]
Studies not reported
High
Cervical dystonia‐specific pain · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Tolerability assessed as dropouts at 4 to 6 weeks: 705 participants (5 RCTs) · cervical dystonia
Botulinum toxin type A leads to lower tolerability assessed as dropouts at 4 to 6 weeks: 705 participants… compared with placebo (high certainty).
1 finding from 1 review
RR 0.48 [0.32, 0.73]
Studies not reported
High
Health‐related quality of life · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Duration of effect 618 participants (5 RCTs) · cervical dystonia
It is very uncertain whether botulinum toxin type A changes duration of effect 618 participants (5 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium within 24 hoursa compared with placebo (low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium within 24 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium between 24 and 48 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in symptoms of delirium within 24 hoursa compared with placebo (low certainty).
1 finding from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
1 finding from 1 review